4 research outputs found
Management of asthma in childhood: study protocol of a systematic evidence update by the Paediatric Asthma in Real Life (PeARL) Think Tank
IntroductionClinical recommendations for childhood asthma are often based on data extrapolated from studies conducted in adults, despite significant differences in mechanisms and response to treatments. The Paediatric Asthma in Real Life (PeARL) Think Tank aspires to develop recommendations based on the best available evidence from studies in children. An overview of systematic reviews (SRs) on paediatric asthma maintenance management and an SR of treatments for acute asthma attacks in children, requiring an emergency presentation with/without hospital admission will be conducted.Methods and analysisStandard methodology recommended by Cochrane will be followed. Maintenance pharmacotherapy of childhood asthma will be evaluated in an overview of SRs published after 2005 and including clinical trials or real-life studies. For evaluating pharmacotherapy of acute asthma attacks leading to an emergency presentation with/without hospital admission, we opted to conduct de novo synthesis in the absence of adequate up-to-date published SRs. For the SR of acute asthma pharmacotherapy, we will consider eligible SRs, clinical trials or real-life studies without time restrictions. Our evidence updates will be based on broad searches of Pubmed/Medline and the Cochrane Library. We will use A MeaSurement Tool to Assess systematic Reviews, V.2, Cochrane risk of bias 2 and REal Life EVidence AssessmeNt Tool to evaluate the methodological quality of SRs, controlled clinical trials and real-life studies, respectively. Next, we will further assess interventions for acute severe asthma attacks with positive clinical results in meta-analyses. We will include both controlled clinical trials and observational studies and will assess their quality using the previously mentioned tools. We will employ random effect models for conducting meta-analyses, and Grading of Recommendations Assessment, Development and Evaluation methodology to assess certainty in the body of evidence.Ethics and disseminationEthics approval is not required for SRs. Our findings will be published in peer reviewed journals and will inform clinical recommendations being developed by the PeARL Think Tank.PROSPERO registration numbers CRD42020132990, CRD42020171624.</p
Prédiction d'une rechute suite à un traitement pour une crise d'asthme chez l'enfant
We prospectively followed 314 children with an acute asthmatic attack who presented and were discharged from the emergency room of the Montreal Children's Hospital, to identify risk factors for relapse, i.e. a second ER visit for asthma within the next 10 days.Ninety-six of the 314 children relapsed, most within 24 hours. Using multiple logistic regression, a predictive model for relapse was developed on 211 patients. The best model contained two variables: (1) the number of ER visits for acute asthma in the previous year and (2) the intake of a short-acting theophylline preparation during the course of the ER treatment. When applied to the subsequent "validation set" sensitivity was 73%, specificity 50% and PPV 41%, thus indicating the robustness of the model. Based on the total sample, the probability of relapse was 31%. Patients with 4 ER visits for acute asthma in the past year (frequent visitors) had a probability of relapse of 45% vs 20% for nonfrequent visitors. The intake of short-acting theophylline during the ER visit reduced the probability of relapse from 50% to 34% among the frequent visitors, and from 30% to 11% among the nonfrequent visitors
Management of asthma in childhood : study protocol of a systematic evidence update by the Paediatric Asthma in Real Life (PeARL) Think Tank
Introduction Clinical recommendations for childhood asthma are often based on data extrapolated from studies conducted in adults, despite significant differences in mechanisms and response to treatments. The Paediatric Asthma in Real Life (PeARL) Think Tank aspires to develop recommendations based on the best available evidence from studies in children. An overview of systematic reviews (SRs) on paediatric asthma maintenance management and an SR of treatments for acute asthma attacks in children, requiring an emergency presentation with/without hospital admission will be conducted. Methods and analysis Standard methodology recommended by Cochrane will be followed. Maintenance pharmacotherapy of childhood asthma will be evaluated in an overview of SRs published after 2005 and including clinical trials or real-life studies. For evaluating pharmacotherapy of acute asthma attacks leading to an emergency presentation with/without hospital admission, we opted to conduct de novo synthesis in the absence of adequate up-to-date published SRs. For the SR of acute asthma pharmacotherapy, we will consider eligible SRs, clinical trials or real-life studies without time restrictions. Our evidence updates will be based on broad searches of Pubmed/Medline and the Cochrane Library. We will use A MeaSurement Tool to Assess systematic Reviews, V.2, Cochrane risk of bias 2 and REal Life EVidence AssessmeNt Tool to evaluate the methodological quality of SRs, controlled clinical trials and real-life studies, respectively. Next, we will further assess interventions for acute severe asthma attacks with positive clinical results in meta-analyses. We will include both controlled clinical trials and observational studies and will assess their quality using the previously mentioned tools. We will employ random effect models for conducting meta-analyses, and Grading of Recommendations Assessment, Development and Evaluation methodology to assess certainty in the body of evidence. Ethics and dissemination Ethics approval is not required for SRs. Our findings will be published in peer reviewed journals and will inform clinical recommendations being developed by the PeARL Think Tank. PROSPERO registration numbers CRD42020132990, CRD42020171624.Peer reviewe
Management of asthma in childhood: study protocol of a systematic evidence update by the Paediatric Asthma in Real Life (PeARL) Think Tank
Introduction Clinical recommendations for childhood asthma are often
based on data extrapolated from studies conducted in adults, despite
significant differences in mechanisms and response to treatments. The
Paediatric Asthma in Real Life (PeARL) Think Tank aspires to develop
recommendations based on the best available evidence from studies in
children. An overview of systematic reviews (SRs) on paediatric asthma
maintenance management and an SR of treatments for acute asthma attacks
in children, requiring an emergency presentation with/without hospital
admission will be conducted. Methods and analysis Standard methodology
recommended by Cochrane will be followed. Maintenance pharmacotherapy of
childhood asthma will be evaluated in an overview of SRs published after
2005 and including clinical trials or real-life studies. For evaluating
pharmacotherapy of acute asthma attacks leading to an emergency
presentation with/without hospital admission, we opted to conduct de
novo synthesis in the absence of adequate up-to-date published SRs. For
the SR of acute asthma pharmacotherapy, we will consider eligible SRs,
clinical trials or real-life studies without time restrictions. Our
evidence updates will be based on broad searches of Pubmed/Medline and
the Cochrane Library. We will use A MeaSurement Tool to Assess
systematic Reviews, V.2, Cochrane risk of bias 2 and REal Life EVidence
AssessmeNt Tool to evaluate the methodological quality of SRs,
controlled clinical trials and real-life studies, respectively. Next, we
will further assess interventions for acute severe asthma attacks with
positive clinical results in meta-analyses. We will include both
controlled clinical trials and observational studies and will assess
their quality using the previously mentioned tools. We will employ
random effect models for conducting meta-analyses, and Grading of
Recommendations Assessment, Development and Evaluation methodology to
assess certainty in the body of evidence. Ethics and dissemination
Ethics approval is not required for SRs. Our findings will be published
in peer reviewed journals and will inform clinical recommendations being
developed by the PeARL Think Tank. PROSPERO registration numbers
CRD42020132990, CRD42020171624